Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Remicade Biosimilar Market Expected To Reach $13.3 Billion By 2030 At 22.2% CAGR
The remicade biosimilar market has experienced a remarkable surge in its overall valuation over recent years. Projections indicate an increase from $4.89 billion in 2025 to $5.97 billion in 2026, reflecting a compound annual growth rate (CAGR) of 22.2%. This expansion during the historical period is largely driven by factors such as the significant financial strain imposed by branded biologics, the expiration of remicade’s patent protection, a rising incidence of autoimmune conditions, favorable government policies facilitating biosimilar approvals, and the adoption of hospital-led bulk purchasing strategies.
The remicade biosimilar market is anticipated to undergo significant expansion over the coming years, with projections indicating it will reach $13.31 billion by 2030, driven by a compound annual growth rate (CAGR) of 22.2%. This forecast period’s growth is fueled by several key factors, including the rising need for affordable biologic treatments, the broadening of biosimilar development programs, increased healthcare spending in developing nations, growing trust from both healthcare providers and patients, and supportive reimbursement policies. Key developments shaping this period include a greater shift toward cost-effective biosimilar options, heightened confidence among prescribers in infliximab biosimilars, the widening use of these products for autoimmune conditions, competitive pricing strategies and tender-based purchasing models, and an increasing presence in emerging healthcare markets.
Download A Free Sample Report For Comprehensive Market Insights:
Remicade Biosimilar Market Demand Drivers Creating New Revenue Opportunities
The anticipated increase in autoimmune disease prevalence is expected to fuel the expansion of the remicade biosimilar market moving forward. Autoimmune diseases involve a situation where the body’s immune system mistakenly targets and harms its own tissues and organs. Remicade biosimilars serve as an effective therapeutic tool for managing symptoms and lessening inflammation linked to these conditions. For example, in February 2024, data from Arthritis Australia, a charitable nonprofit based in Australia that advocates for individuals with arthritis and musculoskeletal issues, indicated that by 2025, around 562,378 Australians are predicted to have rheumatoid arthritis (RA), making up 14% of the total arthritis population. This figure is projected to climb by 33%, reaching roughly 748,721 by 2040. Consequently, the growing frequency of autoimmune diseases is propelling the remicade biosimilar market forward.
Remicade Biosimilar Market Driver: Rising Healthcare Expenditure Boosts Remicade Biosimilar Market Growth
The expansion of the remicade biosimilar market is being substantially driven by rising healthcare expenditure in the coming years. Healthcare expenditure represents the total sum dedicated to healthcare goods and services over a defined timeframe, usually each year. Biologic drugs, including Remicade, generally come with a high price tag. With increasing healthcare spending, there is heightened attention on cost control and more effective resource distribution. Biosimilars present a more affordable option compared to their original biologic drugs, such as Remicade. To illustrate, in November 2023, the Canadian Institute for Health Information, a national body based in Canada, reported that total health spending in the country for 2023 is anticipated to hit $344 billion, or $8,740 per person. This reflects a 2.8% rise from the prior year, which had only a 1.5% increase in health spending in 2022, signaling a strong recovery in healthcare investment. Hence, growing healthcare expenditure will continue to boost the remicade biosimilar market.
Remicade Biosimilar Market Segments: Where Are The Largest Growth Opportunities?
The remicade biosimilar market covered in this report is segmented –
1) By Type: 100mg/10ml, 500mg/50ml
2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis
3) By Application: Blood Disorders, Oncology Diseases
Remicade Biosimilar Market Trends Driving Strategic Industry Expansion
Leading firms in the remicade biosimilar market are investing in novel approaches, such as subcutaneous formulations, to secure a market edge. These subcutaneous versions of Remicade offer a different method of delivering treatment for autoimmune conditions, enabling self-injection and possibly enhancing patient compliance with their therapy regimens. A notable example occurred in March 2024, when Celltrion, a biopharmaceutical company based in South Korea, introduced Zymfentra, a biosimilar to Remicade (infliximab), priced at $6,181.08 for two doses administered over four weeks. This product received FDA approval as the first subcutaneous infliximab formulation intended for maintenance therapy in adults dealing with moderate-to-severe ulcerative colitis and Crohn’s disease. Patients with commercial insurance who are eligible can benefit from copay assistance of $5 per month, whereas those without insurance or with insufficient coverage may obtain Zymfentra at no cost.
Remicade Biosimilar Market Major Participants And Competitive Dynamics
Major companies operating in the remicade biosimilar market are Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., BioXpress Therapeutics SA, Mabion S.A
Access The Complete Remicade Biosimilar Market Report:
Remicade Biosimilar Market Geographic Analysis: Where Is Demand Growing The Fastest?
Europe was the largest region in the remicade biosimilar market in 2025. The regions covered in the remicade biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model